MedTrace Logo

Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial

NCT02678182 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 494

Last updated 2025-06-10

No results posted yet for this study

Summary

To evaluate the efficacy of maintenance therapies following completion of standard first-line chemotherapy in patients with locally advanced or metastatic HER-2 positive or HER-2 negative oesophago-gastric adenocarcinomas.

Conditions

  • Adenocarcinoma of the Oesophagus
  • Adenocarcinoma of the Gastro-oesophageal Junction
  • Adenocarcinoma of the Stomach

Interventions

DRUG

Capecitabine

1250 mg/m2/day, 21 day cycle

DRUG

MEDI4736 (Durvalumab)

IV treatment on days 1\&15 of 28 day cycle

DRUG

Trastuzumab

6mg/kg on day 1 cycle every 21 days

DRUG

Rucaparib

600mg PO twice daily

DRUG

Ramucirumab

ramucirumab 8mg/kg IV day 1 and day 8

Sponsors & Collaborators

  • MedImmune LLC

    collaborator INDUSTRY

  • Clovis Oncology, Inc.

    collaborator INDUSTRY

  • Eli Lilly and Company

    collaborator INDUSTRY

  • AstraZeneca

    collaborator INDUSTRY

  • Royal Marsden NHS Foundation Trust

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2025-04-17
Completion
2027-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02678182 on ClinicalTrials.gov